Steps towards a safer vaccination for Alzheimer’s disease

October 10 2011

Genetic factors influence the immune response to vaccinations for Alzheimer’s disease, which are among the most promising avenues of treatment for the illness. Using a mice model, these factors were studied by a team led by Professor Pierre Aucouturier at the Immune System and Conformational Disorders Laboratory (Inserm/UPMC) in the Hôpital Saint-Antoine. The research shows that in addition to the major histocompatibility complex (MHC) molecules, which present the antigen vaccine to the immune cells, genetic factors, that control some immune cells, influence the quality of response to vaccinations. The results could make it possible to prevent neuroinflammatory reactions, which are major obstacles preventing the use of the vaccination in humans. This study has just been published in The Journal of Immunology.

Vaccination, copyright Inserm, M. Depardieu

Vaccination

Since the beginning of the 2000s, research into Alzheimer’s disease has partly focussed on studying a vaccination composed of amyloid-β peptide (Aß), the accumulation of which in the brain is thought to trigger the disease. Vaccinations with this peptide caused serious neuroinflammatory reactions in 6% of patients. To develop a safer and more effective treatment, it is therefore essential to understand the factors that influence the body’s responses to peptide Aß.

The joint Inserm/UPMC research team, led by Pierre Aucouturier, with Cécile Toly-Ndour and Guillaume Dorothée, conducted its research on mice with different forms of major histocompatibility complex (MHC). The role of these molecules is to present the antigens to the immune cells and they have a wide genetic diversity, which could explain the different responses. Indeed, after vaccination with the peptide Aß, mice with different MHC had different immune cell reactions. Researchers then pushed their studies further. By expressing the MHC from one line of mice to another, they demonstrated that factors in independent from MHC, but related to the genetic background, have a massive influence on the anti-Aß response. They then proved that these factors involve a sub-population of white blood cells (regulatory T cells).

These results provide a new direction to orientate immune cells advantageously, thus improving the immunotherapeutic approach, which remains one of the major hopes in the fight against Alzheimer's. However, these observations made on mice still require validation on human patients.


Back to release list of thematic

Know more

Publication reference

The Journal of Immunology, September 26, 2011 MHC-Independent Genetic Factors Control the Magnitude of CD4+ T Cell Responses to Amyloid-ß Peptide in Mice through Regulatory T Cell-Mediated Inhibition,
Cécile Toly-Ndour, Gabrielle Lui, Maria Manuel Nunes, Martine Bruley-Rosset, Pierre Aucouturier, and Guillaume Dorothée INSERM, Unité Mixte de Recherche S 938, Laboratoire Système Immunitaire et Maladies Conformationnelles, Hôpital Saint-Antoine, F-75012 Paris, France, et Université Pierre et Marie Curie, Université Pierre et Marie Curie, Centre de Recherche Saint-Antoine, Hôpital Saint-Antoine, F-75012 Paris

Researcher contact

Pierre Aucouturier and Guillaume Dorothée
tél. : 01 43 44 34 42

UPMC press contact

Claire de Thoisy-Méchin
Tél. : 01 44 27 23 34, 06 74 03 40 19

^ Top of page
View Edit Create here